Oasis Fertility announced it has raised $50 million in funding from private equity firm Kedaara Capital for a significant minority stake in the company. The transaction will provide an exit to InvAscent, which invested in the company in 2016. It also marked Kedaara’s second investment in the single specialty healthcare segment after ASG Eye Hospitals.

Founded in 2009, Oasis has scaled its network of 26 clinics across 16 cities while doubling its revenues in the last three years. The company also runs an accredited in-house training academy, Oasis School for Human Embryology and Reproductive Medicine (OSHERM), which has trained over 200 medical professionals and published over 60 research papers. Oasis recently launched first-of-its-kind andrology (male infertility) practice called AndroLife.

"We are delighted about leveraging Kedaara’s understanding of the sector and the Indian market. We look forward to this partnership as we embark on a journey to pursue attractive synergistic acquisitions and create a leading fertility platform in India and South Asia to further our core purpose of helping couples achieve parenthood,” said Kiran Gadela, cofounder, Oasis Fertility. The company plans to use the proceeds of the fund raised for strategic acquisitions and expand in India and adjacent overseas markets.